当前位置: 首页 > 期刊 > 《医药产业资讯》 > 2018年第35期
编号:13332114
腹腔内侵袭性纤维瘤病临床治疗回顾(4)
http://www.100md.com 2018年12月15日 《中国医药导报》 2018年第35期
     [13] Crago AM,Chmielecki J,Rosenberg M,et al. Near universal detection of alterations in CTNNB1 and Wnt pathway regulators in desmoid type fibromatosis by whole-exome sequencing and genomic analysis [J]. Genes Chromosomes Cancer,2015,54(10):606-615.

    [14] Van Broekhoven DL,Verhoef C,Grunhagen DJ,et al. Prognostic value of CTNNB1 gene mutation in primary sporadic aggressive fibromatosis [J]. Ann Surg Oncol,2015, 22(5):1464-1470.

    [15] Vitellaro M,Sala P,Signoroni S,et al. Risk of desmoid tumours after open and laparoscopic colectomy in patients with familial adenomatous polyposis [J]. Br J Surg,2014,101(5):558-565.

    [16] Shields CJ,Winter DC,Kirwan WO,et al. Desmoid tumour [J]. Eur J Surg Oncol,2001,27(8):701-706.

    [17] Leithner A,Gapp M,Leithner K,et al. Margins in extra abdominal desmoid tumors:a comparative analysis [J]. J Surg Oncol,2004,86(3):152-156.

    [18] Bocale D,Rotelli MT,Cavallini A,et al. Anti-oestrogen therapy in the treatment of desmoid tumors:a systematic review [J]. Colorectal Dis,2011,13(12):e388-e395.

    [19] Teshima M,Iwae S,Hirayama Y,et al. Nonsteroidal anti-inflammatory drug treatment for desmoid tumor recurrence after surery [J]. Otolaryngol Head Neck Surg,2012, 147(5):978-979.

    [20] Janinis J,Patriki M,Vini L,et al. The pharmacological treatment of aggressive fibromatosis:a systematic review [J]. Ann Oncol,2003,14(2):181-190.

    (收稿日期:2018-01-30 本文編辑:罗乔荔), 百拇医药(吴红学 邹力 柯东 童仕伦)
上一页1 2 3 4